Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Annual Business Results
June 14, 2004
- Wakamoto: Ethical Drug Sales Fall 3% to \6.5 Bil.
June 14, 2004
- MEDICAL DEVICE NEWS IN BRIEF
June 14, 2004
- CORPORATE ROUNDUP NEWS IN BRIEF
June 14, 2004
- DIAGNOSTIC NEWS IN BRIEF
June 14, 2004
- SEMIANNUAL SALES
June 14, 2004
- New Drugs Prolong Longevity by 3 Weeks Per Year: Dr Lichtenberg
June 14, 2004
- BULLETIN
June 14, 2004
- MR-Kun Service Could Begin This Autumn in the US: So-net M3
June 14, 2004
- Hakuhodo to Support Drug Companies to Educate Patients
June 14, 2004
- Nikken Chemicals: Drug Division Sales Down 3.8% to \41.2 Bil.
June 7, 2004
- OTC NEWS IN BRIEF
June 7, 2004
- Nippon Shinyaku: Drug Division Sales Down 4.4% to \42.4 Bil.
June 7, 2004
- Annual Business Results
June 7, 2004
- Fuso: 1st Increase in Ordinary Profits in 3 Years
June 7, 2004
- DIAGNOSTIC NEWS IN BRIEF
June 7, 2004
- Teikoku Hormone: Drug Division Sales Slip 4.1% to \18.6 Bil.
June 7, 2004
- Annual Business Results
June 7, 2004
- Sumitomo Pharmaceuticals: Sales Fall 1% to \136.9 Bil.
June 7, 2004
- Semiannual Business Results
June 7, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…